These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 19158152

  • 1. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE.
    Mebazaa A, Nieminen MS, Filippatos GS, Cleland JG, Salon JE, Thakkar R, Padley RJ, Huang B, Cohen-Solal A.
    Eur J Heart Fail; 2009 Mar; 11(3):304-11. PubMed ID: 19158152
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol.
    Duygu H, Turk U, Ozdogan O, Akyuz S, Kirilmaz B, Alioglu E, Gunduz R, Bozkaya YT, Turkoglu C, Payzin S.
    Cardiovasc Ther; 2008 Mar; 26(3):182-8. PubMed ID: 18786088
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effect of baseline characteristics on mortality in the SURVIVE trial on the effect of levosimendan vs dobutamine in acute heart failure: Sub-analysis of the Finnish patients.
    Kivikko M, Pollesello P, Tarvasmäki T, Sarapohja T, Nieminen MS, Harjola VP.
    Int J Cardiol; 2016 Jul 15; 215():26-31. PubMed ID: 27107540
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
    Adamopoulos S, Parissis JT, Iliodromitis EK, Paraskevaidis I, Tsiapras D, Farmakis D, Karatzas D, Gheorghiade M, Filippatos GS, Kremastinos DT.
    Am J Cardiol; 2006 Jul 01; 98(1):102-6. PubMed ID: 16784930
    [Abstract] [Full Text] [Related]

  • 10. Natriuretic peptide-guided levosimendan therapy for heart failure: a promising new approach.
    Giamouzis G, Giannakoulas G, Tsarpalis K, Agha SA, Georgiopoulou V, Kalogeropoulos A, Karvounis H, Butler J.
    Int J Cardiol; 2008 Aug 01; 128(1):91-3; author reply 94-6. PubMed ID: 18495268
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial.
    Cleland JG, Takala A, Apajasalo M, Zethraeus N, Kobelt G.
    Eur J Heart Fail; 2003 Jan 01; 5(1):101-8. PubMed ID: 12559222
    [Abstract] [Full Text] [Related]

  • 13. A struggle to SURVIVE: to abandon or not to abandon levosimendan?
    Butler J, Giamouzis G, Giannakoulas G.
    Cardiovasc Drugs Ther; 2007 Oct 01; 21(5):401-2. PubMed ID: 17701453
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Efficacy and safety of intravenous levosimendan compared with dobutamine in decompensated heart failure].
    Wang L, Cui L, Wei JP, Li GP, Qi GX, Hao YM, Wang WZ, Li HM, Liu J, Jiang DJ, Zhang YD.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2010 Jun 01; 38(6):527-30. PubMed ID: 21033135
    [Abstract] [Full Text] [Related]

  • 17. How to treat acute decompensated heart failure in the 'beta-blocker era'?
    Marcondes-Braga FG, Mangini S, Ayub-Ferreira SM, Bocchi EA, Bacal F.
    Eur J Heart Fail; 2010 Aug 01; 12(8):893-4. PubMed ID: 20675672
    [No Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of levosimendan in patients with acute heart failure.
    Fedele F, D'Ambrosi A, Bruno N, Caira C, Brasolin B, Mancone M.
    J Cardiovasc Pharmacol; 2011 Oct 01; 58(4):363-6. PubMed ID: 21697728
    [Abstract] [Full Text] [Related]

  • 19. The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure.
    Cavusoglu Y.
    Expert Opin Pharmacother; 2007 Apr 01; 8(5):665-77. PubMed ID: 17376021
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.